11.05.2020
Therapeutics
$914,611.99
24 months
Crohn's Fistulizing Program – Investigator Initiated Clinical Trials
Perianal fistulizing disease is a common, devastating complication in Crohn's disease that is often refractory to treatment. This study aims to provide evidence for the safety and efficacy of mesenchymal stem cells to enable larger scale clinical trials to support regulatory approval of this therapy for patients suffering with this complication.